Cargando…

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

PURPOSE: Trastuzumab deruxtecan (T-DXd, formerly DS-8201a) is a novel human epidermal growth factor receptor 2 (HER2)-targeted antibody drug conjugate (ADC) with a topoisomerase I inhibitor payload. A dose escalation and expansion phase I study evaluated the safety and activity of T-DXd in patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Modi, Shanu, Park, Haeseong, Murthy, Rashmi K., Iwata, Hiroji, Tamura, Kenji, Tsurutani, Junji, Moreno-Aspitia, Alvaro, Doi, Toshihiko, Sagara, Yasuaki, Redfern, Charles, Krop, Ian E., Lee, Caleb, Fujisaki, Yoshihiko, Sugihara, Masahiro, Zhang, Lin, Shahidi, Javad, Takahashi, Shunji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2020
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280051/ https://www.ncbi.nlm.nih.gov/pubmed/32058843 http://dx.doi.org/10.1200/JCO.19.02318

Ejemplares similares

Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan
por: Moss, Nelson S, et al.
Publicado: (2022)

Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2‐Positive or HER2‐Low Metastatic/Unresectable Breast Cancer
por: Shimomura, Akihiko, et al.
Publicado: (2022)

Trastuzumab deruxtecan for breast cancer
Publicado: (2022)

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
por: Jerusalem, Guy, et al.
Publicado: (2022)

Exposure‐Response Relationships in Patients With HER2‐Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan
por: Yin, Ophelia, et al.
Publicado: (2021)

[Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti–CTLA-4 antibody in a mouse model
por: Iwata, Tomomi Nakayama, et al.
Publicado: (2019)

Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies
por: Powell, C.A., et al.
Publicado: (2022)

Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
por: Kabraji, Sheheryar, et al.
Publicado: (2023)

Real-World Data of Trastuzumab Deruxtecan for Advanced Gastric Cancer: A Multi-Institutional Retrospective Study
por: Matsumoto, Toshihiko, et al.
Publicado: (2022)

Safety of trastuzumab deruxtecan: A meta‐analysis and pharmacovigilance study
por: Guo, Zihan, et al.
Publicado: (2022)

Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer
por: Kotani, Daisuke, et al.
Publicado: (2021)

Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
por: Indini, Alice, et al.
Publicado: (2021)

Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer
por: Rugo, H.S., et al.
Publicado: (2022)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)
por: Niikura, Naoki, et al.
Publicado: (2023)

Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer
por: Makhlin, Igor, et al.
Publicado: (2022)

Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy
por: McNamara, Blair, et al.
Publicado: (2023)

Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective
por: Henning, Jan-Willem, et al.
Publicado: (2023)

Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
por: DiPeri, Timothy P., et al.
Publicado: (2023)

Adverse Event Profile Differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: A Real-world, Pharmacovigilance Study
por: Liu, Fen, et al.
Publicado: (2023)

Two cases of trastuzumab deruxtecan‐induced interstitial lung disease in advanced breast cancer
por: Gocho, Kyoko, et al.
Publicado: (2022)

Successful Trastuzumab-Deruxtecan Rechallenge After Interstitial Lung Disease: A Case Report
por: de Weger, Vincent A., et al.
Publicado: (2023)

Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan
por: Baba, Tomohisa, et al.
Publicado: (2023)

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors
por: Takahashi, Shunji, et al.
Publicado: (2021)

Dose-reduced trastuzumab deruxtecan can be safely used in liver failure and active leptomeningeal metastases
por: Higashiyama, Nicole, et al.
Publicado: (2020)

Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer
por: Shitara, Kohei, et al.
Publicado: (2021)

Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials
por: Xu, Hanyue, et al.
Publicado: (2022)

A Case of HER2 Mutated Colorectal Cancer Treated Successfully With Fam-Trastuzumab Deruxtecan
por: Reddy, Aswanth, et al.
Publicado: (2023)

Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
por: Alder, Laura, et al.
Publicado: (2023)

Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer
por: Shi, Demin, et al.
Publicado: (2023)

Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
por: Antonarelli, G., et al.
Publicado: (2023)

Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
por: Nakajima, Hiromichi, et al.
Publicado: (2022)

Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape
por: Adams, E., et al.
Publicado: (2021)

Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors
por: Yin, Ophelia, et al.
Publicado: (2020)

Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan
por: Bardia, Aditya, et al.
Publicado: (2022)

Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report
por: Riudavets, Mariona, et al.
Publicado: (2022)

Enhertu (Fam-trastuzumab-deruxtecan-nxki) – Revolutionizing treatment paradigm for HER2-Low breast cancer
por: Siddiqui, Tasmiyah, et al.
Publicado: (2022)

Correction: A Case of HER2 Mutated Colorectal Cancer Treated Successfully With Fam-Trastuzumab Deruxtecan
por: Reddy, Aswanth, et al.
Publicado: (2023)

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial
por: Mosele, Fernanda, et al.
Publicado: (2023)

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
por: Krop, Ian E., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vggem7t1mh7dtr8d43sja9osrc